Opinion
Video
1L treatment of lower-risk MDS beyond luspatercept
Author(s):
Medical experts explore alternative treatment options for lower-risk myelodysplastic syndrome (LR-MDS) patients who are not suitable candidates for first-line luspatercept therapy.
- For patients who are not suitable to receive 1L luspatercept for LR-MDS, what alternate treatment options would you consider?
- What other trials on the horizon are you excited for in the 1L treatment of lower-risk MDS?
Related Videos
Related Content
